BOSTON–(BUSINESS WIRE)–908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time … [Read more…]
– Board appointments following recent $95 million CAD Series C Financing MONTREAL–(BUSINESS WIRE)–#EdMathers–Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General … [Read more…]
Third quarter GAAP net income was $6.68 per share, including net negative adjustment items of $0.85 per share. Adjusted net income was $7.53* per share. Operating revenue grew 11.5% over the prior year quarter to $39.6 billion. Operating gain grew 10.2% over the prior year quarter to $2.3 billion. Medical enrollment increased 2.2 million members … [Read more…]
AUSTIN, Texas, SOUTH SAN FRANCISCO & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to … [Read more…]
AUSTIN, Texas–(BUSINESS WIRE)–#clinicalpanel–Prodigy Care Services has formed a clinical panel to provide insight and guidance to its workers’ compensation pharmacy benefits manager, ProdigyRx. The panel brings expertise in a wide range of pharmacy management areas to support ProdigyRx’s clinical programs, evaluate emerging therapies, and consult on extremely complex cases. Initial members are Maud Boateng, Pharm.D., … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Branded Generics Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global branded generics market is expected to grow from $280.40 billion in 2021 to $303.10 billion in 2022 at a compound annual growth rate (CAGR) of 8.1%. The branded generics market is expected to reach $414.35 billion in 2026 … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Asparaginase Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type, Application, End-Use Industry, and Geography” report has been added to ResearchAndMarkets.com’s offering. The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028. It is expected to grow with a CAGR … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Medical Device Testing Services Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. The global medical device testing services market is estimated to surge at a CAGR of 14.79% from a market value of US$32.434 billion in 2020, to achieve a market value of US$85.156 billion by the … [Read more…]
Aqemia leverages its unique Deep Physics-powered AI to uncover breakthrough drug candidates at scale. The €30 million Series A funding round was co-led by Eurazeo and Bpifrance, through its Large Venture fund. This capital will be used to scale Aqemia’s proprietary drug discovery platform and its proprietary therapeutic assets pipeline, with a first emphasis on … [Read more…]
